Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BHP Billiton Limited (BHP) vs Cassava Sciences Inc (FLNA) Price & Performance

BHP Billiton LimitedTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

BHP Billiton Limited vs Cassava Sciences Inc — how do they compare? BHP Billiton Limited trades at $90.59 (market cap $229.15B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: BHP Billiton Limited is far larger — about 4799× Cassava Sciences Inc's market cap, and BHP Billiton Limited pays a 2.95% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

BHPFLNA
Market Cap
$229.15B$47.75M
Sector
Basic MaterialsHealth
52-Week High
$93.15$4.64
52-Week Low
$52.14$0.87
Enterprise Value
$243.35B-$34.93M
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BHP Billiton Limited

BHP trades at $90.61, up 0.22% with a bullish technical signal supported by moving averages. The company reported mixed Q4 2025 earnings, missing EPS estimates but maintaining strong profitability with 18.97% net margins. Recent operational challenges include strikes at Port Hedland iron ore operations, while copper production declines in Chile. Valuation metrics show a P/E of 22.36 and P/B of 4.54, reflecting premium pricing relative to historical levels.

The outlook remains cautiously optimistic with analyst consensus leaning hold (64.52%) amid labor disputes and production volatility. Key opportunities include exposure to AI-driven copper demand growth, while risks center on strike impacts and fluctuating commodity prices. The stock's current technical strength faces fundamental headwinds from operational disruptions.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

About BHP Billiton Limited

BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.

Read more on BHP

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA